Fredun Pharmaceuticals Ltd
Fredun Pharmaceuticals Q2 FY26 earnings call: Revenue & Margins
Q2 FY26 earnings call: what management said on revenue, margins and capex.
Top 10 Pharmaceuticals & Biotechnology companies on management guidance
See the sector's top 10 — free with your mobile number.
The short version
Fredun Pharmaceuticals plans steady, founded growth across businesses with no year of de-growth in the last 18 years. Fredun Pharmaceuticals expects steady, founded growth with no year of de-growth in the past 18 years, aiming to continue this trajectory.
From Fredun Pharmaceuticals Ltd's Q2 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- Fredun Pharmaceuticals plans steady, founded growth across businesses with no year of de-growth in the last 18 years.
- Vintage business expected to grow sustainably at around 15% CAGR for the next 7 to 9 years driven by registrations and existing channels.
- New age businesses (Pet Care, Nutraceuticals, Mobility) are growing month-on-month with detailed 3 to 7-year plans for each vertical.
- Wagr e-commerce platform aims for a multi-million dollar monthly revenue in 5 to 7 years.
- By FY'29, management targets INR 90 crores PAT, with potential for higher performance depending on market conditions.
- Pet Care division to significantly scale with expansion into 52 countries; strong domestic bases being built to support exports.
2 more points from Fredun Pharmaceuticals Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Fredun Pharmaceuticals Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Fredun Pharmaceuticals plans capex and strategic investments primarily for new product development, team building, marketing, and distribution.
- Recent fundraising will be used as growth capital to accelerate sustainable growth in new age businesses towards 2029-2030.
- Planned investments include INR4-5 crores over the next 18-24 months and another INR5-7 crores later for the Wagr e-commerce platform to align and promote sales.
- The company is expanding manufacturing capacity with a state-of-the-art facility at Palghar and adding contract manufacturing locations to support product portfolio growth.
- Capex also includes infrastructure to increase production, especially for nutraceuticals, mobility, cosmetics, and pet care products.
2 more points from Fredun Pharmaceuticals Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Fredun Pharmaceuticals Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- Fredun Pharmaceuticals has received an "unbelievable" and "crazy phenomenal" response for their Snacky Jain product.
- The order book for Snacky Jain has surpassed their initial expectations.
- Due to high demand, they had to revisit manufacturing and procurement plans.
- Snacky Jain is expected to be in stores across certain geographies by the end of November 2025.
- Within the next 6 months, it is planned to be available in most parts of India.
2 more points from Fredun Pharmaceuticals Ltd's call on order book
Create a free account to keep reading this call
Fredun Pharmaceuticals Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹213 Cr, net profit ₹11 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Fredun Pharma's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Bajaj Healthcare (Q2 FY26)
For HYE (Half Year Ending) Sept 2025, Total Income reported is ₹299.28 crore. Key investor presentation takeaways from Bajaj Healthcare Ltd's Q2 FY26 investor p
- Infinium Pharma (Q2 FY26)
Revenue from Operations for H1FY26: Rs 84.05 crore, a 1% YoY increase from Rs 82.98 crore in H1FY25 (Page 22). Key investor presentation takeaways from Infinium
- Wanbury (Q2 FY26)
Q2FY26 Revenue from Operations: ₹160.06 Crore . Key investor presentation takeaways from Wanbury Ltd's Q2 FY26 investor presentation — and how it ranks against
- Balaxi Pharma (Q2 FY26)
Revenue for Q2 FY26: ₹56.17 crore . Key investor presentation takeaways from Balaxi Pharma's Q2 FY26 investor presentation — and how it ranks against sector pee
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Fredun Pharmaceuticals Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Fredun Pharmaceuticals Ltd Q2 FY26 results?
Fredun Pharmaceuticals plans steady, founded growth across businesses with no year of de-growth in the last 18 years. Fredun Pharmaceuticals expects steady, founded growth with no year of de-growth in the past 18 years, aiming to continue this trajectory.
What is Fredun Pharmaceuticals Ltd share price analysis?
Fredun Pharmaceuticals Ltd currently shows a neutral. The stock trades at a P/E of 57.6 with a market cap of ₹2,560 Cr. Investors should review the full earnings analysis for detailed insights.
Is Fredun Pharmaceuticals Ltd planning capital expenditure?
Fredun Pharmaceuticals plans capex and strategic investments primarily for new product development, team building, marketing, and distribution.
Keep Fredun Pharmaceuticals Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.